MARKET

IMMP

IMMP

Immutep
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.890
-0.070
-1.77%
After Hours: 3.810 -0.08 -2.06% 19:11 09/24 EDT
OPEN
3.910
PREV CLOSE
3.960
HIGH
3.935
LOW
3.820
VOLUME
63.05K
TURNOVER
--
52 WEEK HIGH
7.95
52 WEEK LOW
1.530
MARKET CAP
291.03M
P/E (TTM)
-0.9767
1D
5D
1M
3M
1Y
5Y
Head and Neck Squamous Cell Carcinoma (HNSCC) Treatment and Drugs Market Global Industry Analysis, Size, Share, Growth and Forecast 2028
Research Nester published a report titled which delivers detailed overview of the head and neck squamous cell carcinoma (HNSCC) treatment and drugs in terms of market segmentation by drug class, distribution channel and by region.
AmericaNewsHour · 2d ago
Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021
SYDNEY, Australia, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to an...
GlobeNewswire · 4d ago
Immutep to present final Overall Survival data from Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021
Immutep Limited (NASDAQ: IMMP) is pleased to announce it will report final Overall Survival (OS) data from its Phase IIb AIPAC clinical trial evaluating lead product candidate eftilagimod alpha ("efti" or "IMP321") in metastatic breast cancer at the Socie...
Benzinga · 4d ago
BRIEF-Immutep Completes Recruitment Of 2nd Line PD-1/PD-L1 Refractory NSCLC Patients In Tacti-002
reuters.com · 09/01 12:36
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
Immutep Limited (NASDAQ: IMMP) announces that the last patient has been enrolled and safely dosed in Stage 2 of Part B of its Phase II TACTI-002 study (also designated KEYNOTE-798). This completes the recruitment of 2nd line PD-1/PD-L1 refractory non-small...
Benzinga · 09/01 09:27
Immutep's Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline; Terms Not Disclosed
Immutep's Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 31 August 2021 – Immutep Limited ((ASX: IMM, NASDAQ:IMMP)
Benzinga · 08/31 12:08
Immutep Announces Chinese Patent Grant For LAG-3 Antagonist Antibody LAG525
SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), is pleased to announce the grant of patent no. ZL201580013695.X
Benzinga · 08/27 12:02
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/27 11:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMMP. Analyze the recent business situations of Immutep through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMMP stock price target is 8.35 with a high estimate of 8.91 and a low estimate of 7.92.
EPS
Institutional Holdings
Institutions: 34
Institutional Holdings: 8.97M
% Owned: 11.99%
Shares Outstanding: 74.82M
TypeInstitutionsShares
Increased
4
2.04M
New
17
2.50M
Decreased
4
217.65K
Sold Out
2
364.89K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman
Russell Howard
Chief Executive Officer/Executive Director
Marc Voigt
Non-Executive Vice Chairman
Pete Meyers
Chief Operating Officer/General Counsel/Secretary
Deanne Miller
Chief Scientific Officer
Frederic Triebel
Non-Executive Director
Grant Chamberlain
No Data
About IMMP
Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

Webull offers kinds of Immutep Ltd stock information, including NASDAQ:IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.